Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Brean Murray Ups Adolor to Strong Buy

Brean Murray upgraded Adolor (ADLR) to strong buy from accumulate, citing expectations for positive results from trials of the company's new treatment for obstructive bowel disease.

Analyst Jonathan Aschoff notes very clean Phase 2 trial results presented thus far in 522 patients who used the treatment. He thinks regulatory approval of the treatment would be material to the company's profitability, given factors such as the appeal of an oral medication for obstructive bowel disease. He says shares have drifted several dollars lower over the past two months, but he believes significant upside potential exists in them. He has $34 stock price target.

blog comments powered by Disqus